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The Overall Anxiety Severity and Impairment Scale (OASIS) is a self-report questionnaire
designed to evaluate the severity and functional impairment associated with anxiety. Given
its transdiagnostic nature, it can be used indistinctly across anxiety and depressive disor-
ders. In this study, the psychometric properties of the online version of the OASIS were eval-
uated in a Spanish clinical sample with emotional disorders. Patients (n = 583) with anxiety
(n = 250) and depression (n = 333) with a mean age of 37.21 (SD = 12.22), underwent a
diagnostic interview and questionnaires assessing anxiety, depression, positive and nega-
tive affect, and quality of life. Factorial structure, internal consistency, convergent and dis-
criminant validity, cutoff scores, and sensitivity to change were analyzed. Confirmatory
Factor Analysis yielded a unidimensional factor structure, consistent with previous valida-
tions of the instrument. The analyses showed good internal consistency and adequate con-
vergent and discriminant validity, as well as sensitivity to change. A cutoff score of 7.5 was
found to meet the criteria used in this study to select the optimal cutoff point. Overall, in this
study, the psychometric properties of the online version of the OASIS were found to be
appropriate. The brevity and ease of use of the OASIS support its adequacy as a valid mea-
sure of anxiety severity and impairment in Spanish clinical samples with anxiety and
depression.
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Introduction
Anxiety and depressive disorders, also known as emotional disorders (ED), are prevalent [1,2]
and costly [3,4] and an important cause of suffering and disability worldwide [5,6]. Moreover,
the literature has shown the high comorbidity rates among anxiety disorders, and between
anxiety and depressive disorders [7].
Along with depression, anxiety disorders are one the most prevalent disorders, with a
12-month prevalence of 18.1% [8], and a lifetime prevalence of 28.8% [1]. In Spain, the
12-month prevalence of an anxiety disorder has been estimated at 6.2%, and the lifetime
prevalence at 9.3% [9]. Anxiety disorders are associated with important impairments [10],
significantly poorer quality of life [11], and high rates of comorbidity with other anxiety
disorders and with depression [2,7]. Therefore, the development of treatments for anxiety
is a key aspect in addressing this important health problem. Moreover, the impact of these
interventions cannot be ascertained without the use of appropriate assessment instru-
ments. In this vein, despite the importance of evidence-based assessment (i.e. the use of
research and theory to guide the selection of the most appropriate instrument for the
assessment of a specific construct) [12], the attention paid to assessment is more recent
than the importance given to evidence-based treatments, first described in a book pub-
lished ten years earlier [13]. Therefore, the development and validation of rigorous assess-
ment tools is an important task for researchers and clinicians involved in the assessment
and treatment of anxiety disorders. In this vein, the need for digital versions of pen and
paper scales has increased exponentially due to the proliferation of web-based interven-
tions [14,15]. Nevertheless, the literature highlights that paper and online versions of the
same instrument show strong correlations but may differ in psychometric properties [14].
Therefore, as research on web-based treatments advances, it becomes crucial to develop
and validate assessment instruments that can be applied online [16].
Currently, there are a number of measurement tools to assess overall anxiety, such as the
Beck Anxiety Inventory [17] or the State-Trait Anxiety Inventory [18]. These scales have been
translated into Spanish and validated in previous research [19–21]. Additionally, several
instruments have been developed and validated for the assessment of the symptoms associated
with each of the different anxiety disorders (i.e. disorder-specific symptoms), such as the Penn
State Worry Questionnaire [22] for generalized anxiety disorder, the Panic Disorder Severity
Scale [23] for panic disorder and/or agoraphobia, and the Social Interaction Anxiety Scale [24]
for social anxiety disorder. However, all these instruments focus on the assessment of individ-
ual anxiety symptoms (i.e. the occurrence of cognitive, emotional, and physiological symp-
toms), but they do not provide a measure of the global severity and impairment associated
with these problems.
The Overall Anxiety Severity and Impairment Scale (OASIS) is a short scale made up of
5 items developed to assess the severity and impairment associated with anxiety disorders
and/or symptoms [25–27]. Two advantages of the OASIS include its brevity and ease of
use and its transdiagnostic nature. Regarding brevity, the need for short scales (i.e. less
than 10 items) has been highlighted in the literature [25]. Several advantages have been
indicated in this regard, such as the fact that it is an easier way to obtain relevant data in
clinical settings such as primary care (where resources are normally limited) [25,28] or
that symptoms can be monitored throughout a treatment [12]. For instance, this latter
aspect might be particularly useful when it is necessary to evaluate anxiety symptoms
repeatedly throughout a treatment (i.e. after each treatment module or session). Finally,
in a more general way, even though brevity might compromise a scale’s validity [29], com-
pared to longer scales, the use of shorter scales provides a more efficient way to collect
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data and maximize the representativeness of the sample [28]. In addition, from a trans-
diagnostic perspective, it is logical to develop and validate measures that capture the
severity and impairment of anxiety disorders, regardless of the specific anxiety disorder
suffered by the patients [25,30]. Following the DSM-IV-TR guidelines to establish the
severity and associated impairment caused by anxiety, the five items on the OASIS were
developed in an attempt to capture the most important domains of anxiety that are com-
mon to all anxiety disorders, namely, severity (i.e. frequency and intensity), behavioral
avoidance, and functional impairment (i.e. work and social interference) [26]. Because
the OASIS focuses on the severity and functional consequences of anxiety, rather than the
occurrence of specific anxiety symptoms (which might vary depending on the specific
presentation of each patient), the scale can be used in a transdiagnostic manner across dif-
ferent anxiety disorders. Given the theoretical and empirical association between anxiety
and depression [2] and the high comorbidity rates between these disorders, the scale can
also be used to assess the severity and impairment of anxiety in individuals with
depression.
Previous versions of the OASIS have been validated in both clinical [25,31–33] and non-
clinical samples [26,27]. In sum, the OASIS has shown sound psychometric properties in the
existing literature. Nevertheless, to our knowledge, the OASIS has not yet been validated in
Spanish clinical samples with anxiety and depressive disorders. Furthermore, most of the pre-
vious work in clinical populations has focused on patients with principal diagnoses of anxiety
disorders, with some exceptions [31,32] that also included patients with a principal diagnosis
of depression. However, in these studies, the proportion of patients with depression was low,
compared to patients with anxiety [31]. Regarding the online validation of the OASIS, to our
knowledge, only one study in the literature has used online surveys [32]. However, even
though this study showed good psychometric properties, it relied on patients’ self-reports to
establish a formal diagnosis, rather than well-validated measures such as diagnostic interviews
or self-report questionnaires.
Current study
In this study, we aimed to contribute to filling this gap by analyzing the psychometric proper-
ties of the OASIS in two clinical subsamples of individuals with emotional disorders: a subsam-
ple with a principal diagnosis of anxiety (n = 250) and a subsample with a principal diagnosis
of depression (n = 333). Specific objectives were: a) to examine how the scale performs in
patients with anxiety disorders vs. depressive disorders; b) to examine the scale’s factorial
structure, reliability, and validity; c) to obtain cutoff scores; and d) to analyze sensitivity to
change. To the best of our knowledge, this is the first study to evaluate the psychometric prop-
erties of the online version of the OASIS in a sample of adults with anxiety and depressive dis-
orders in the Spanish population.
Methods
Spanish translation of the OASIS
First, a native Spanish-speaker who was aware of the purpose of the study translated the
OASIS items from English to Spanish. Second, a Spanish-English bilingual speaker who was
not familiar with the questionnaire performed a back-translation from Spanish to English. The
person involved in the translation process is a native English speaker who has been living in
Spain for many years and is fluent in both languages. The two English versions were com-
pared, and the Spanish version of the OASIS was judged to be an accurate translation of the
original English version.
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Procedure
The sample was recruited from patients attending the Emotional Disorders Clinic at Jaume I
University (Castellon, Spain), whose principal focus is the treatment of ED using Information
and Communication Technologies such as web-based interventions. Individuals who were
waiting to receive an online treatment were invited to participate in the study, and those who
agreed to participate provided written, informed consent. Only participants with a principal
diagnosis of an emotional disorder (i.e. anxiety and depressive disorders) were considered for
the study. All participants were assessed with a structured diagnostic interview, and a battery
of questionnaires. All these measurement tools are described in detail in the Instruments sec-
tion. The study was approved by the Ethics Committee of Universitat Jaume I.
Participants
A total of 583 individuals with a mean age of 37.21 years (SD = 12.22; range: 18–68 years old)
took part in the study. Most participants were female (n = 421; 72.21%), married or living with
a partner (n = 273; 46.83%), and had completed higher education studies (n = 371; 56.3%). All
of the participants were Caucasian. Regarding their diagnoses, 333 patients had a principal
diagnosis of a mood disorder (i.e. major depressive disorder, dysthymic disorder, mood disor-
der not otherwise specified), and 250 had a principal diagnosis of an anxiety disorder. In all,
more than half the sample had at least one comorbid anxiety or depressive disorder (53.5%).
Diagnostic assessments were performed by pre-doctoral students who had been previously
trained in the use of the diagnostic interview. A full description of the patients’ sociodemo-
graphic and clinical data is displayed in Table 1.
Instruments
Diagnostic interview. Mini-International Neuropsychiatric Interview [34]. The MINI
is a short, structured clinical interview designed to perform diagnoses according to the
DSM-IV and ICD-10 criteria. It has shown excellent test-retest and interrater reliability, as
well as high predictive validity rates. The Spanish validation was used in this study [35].
Self-reported questionnaires. Overall Anxiety Severity and Impairment Scale (OASIS)
[25]. The OASIS is a 5-item self-report scale that evaluates the frequency and severity of anxi-
ety symptoms, the functional impairment related to these symptoms (i.e. school, work, home,
or social impairment), and behavioral avoidance. Each item instructs respondents to endorse
one of five responses that best describes their experiences over the past week. Response items
are coded from 0 to 4, added together to obtain a total score ranging from 0 to 20. Previous
studies have shown high internal consistency (α = 0.80), test-retest reliability, and convergent
and discriminant validity [25–27]. In the current study, Cronbach’s alpha coefficient for the
five items on the OASIS was good (0.86).
Beck Anxiety Inventory (BAI) [17]. This is a 21-item self-report questionnaire for the mea-
surement of anxiety symptoms experienced during the past week. Each item is rated from 0 to
3 (i.e. not at all, mildly, moderately, severely), added together to obtain a maximum score of
63. The BAI has demonstrated good to excellent internal consistency in prior validations of the
scale (.85-.94), as well as adequate convergent and divergent validity [20]. Cronbach’s alpha for
the BAI in the present study was excellent (.91).
Beck Depression Inventory (BDI-II) [36]. The BDI-II is a 21-item self-report scale
designed to assess depressive symptoms experienced during the past week. Items are rated on
a Likert scale rated from 0 to 3, and the total score ranges from 0 to 63. The BDI-II has shown
optimal validity and reliability in both clinical and nonclinical samples [36–38]. Cronbach’s
alpha for the BDI-II in the present study was excellent (0.91).
A brief online transdiagnostic measure: The OASIS among Spanish patients with emotional disorders
PLOS ONE | https://doi.org/10.1371/journal.pone.0206516 November 1, 2018 4 / 18
Overall Depression Severity and Impairment Scale (ODSIS) [39]. The ODSIS consists of
five items that measure the severity and impairment related to depression, as well as its inter-
ference with school, work, and social life. The measure has shown excellent internal consis-
tency (α = 0.94 in an outpatient sample, 0.92 in a community sample, and 0.91 in a student
sample) [39] and good convergent and discriminant validity. In the present study, the ODSIS
showed excellent internal consistency (0.93).
Positive and Negative Affect Schedule (PANAS) [40]. The PANAS is a self-report mea-
sure that evaluates two dimensions on two independent scales: positive (PANAS-P) and
Table 1. Sociodemographic and clinical characteristics of the sample (n = 583).
Age in years, Mean (SD) 37.21 (12.22)
Sex, n (%) Female 421 (72.21)
Male 162 (27.79)
Relationship status, n (%) Single 235 (40.31)
Married/de facto 279 (47.86)
Divorced 62 (10.63)
Widowed 7 (1.20)
Education level, n (%) Basic 94 (16.12)
Medium 179 (30.70)
Superior 310 (53.17)
Principal diagnosis, n (%) Major depressive disorder 318 (34.5)
Generalized anxiety disorder 99 (17)
Social anxiety disorder 57 (9.8)
Panic disorder/agoraphobia 50 (8.6)
Obsessive-compulsive disorder 14 (2.4)
Dysthymic disorder 13 (2.2)
Anxiety disorder NOS 12 (2.1)
Specific phobia 10 (1.7)
Postraumatic stress disorder 4 (0.7)
Mood disorder NOS 2 (0.3)
Intermittent explosive disorder 2 (0.3)
Somatoform disorder 1 (0.2)
Hypochondriasis 1 (0.2)
Number of comorbid disorders, n (%) 0 271 (46.5)
1 210 (36)
2 80 (13.7)
� 3 22 (3.8)







OASIS = Overall Anxiety Severity and Impairment Scale; BAI = Beck Anxiety Inventory; BDI-II = Beck Depression
Inventory-II; ODSIS = Overall Depression Severity and Impairment Scale; PANAS-P = Positive and Negative Affect
Schedule-Positive Affect; PANAS-N = Positive and Negative Affect Schedule-Negative Affect;
QLI = Multidimensional Quality of Life Questionnaire
https://doi.org/10.1371/journal.pone.0206516.t001
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negative affect (PANAS-N). Each scale is composed of 10 items coded in a range from 10 to 50
points. The PANAS has shown excellent convergent and divergent validity, as well as high
internal consistency [40–42]. In the current study, Cronbach’s alpha was excellent for the
PANAS-P (0.93) and good for the PANAS-N (0.88).
Multidimensional Quality of Life Questionnaire (QLI) [43]. The QLI is a self-report ques-
tionnaire that consists of 10 items aimed at assessing quality of life in ten areas: psychological
well-being, physical well-being, emotional and social support, interpersonal functioning, self-
care and independent functioning, community and service support, occupational functioning,
self-realization, spiritual satisfaction, and an overall assessment of quality of life. The Spanish
version of the QLI has shown good internal consistency and test-retest reliability in previous
studies [44]. Cronbach’s alpha for the QLI in the present study was excellent (0.90).
Data analysis
First, descriptive statistics (mean, standard deviation, skewness, and kurtosis) for the anxiety
and depression subsamples were calculated for all the measures. Next, one-way ANOVAs were
calculated to analyze whether there were significant differences in the scores on the OASIS
based on gender, marital status, studies, and diagnosis. Furthermore, correlations between age
and the OASIS score were calculated in order to study whether there were any associations
between these variables. In addition, reliability was analyzed by calculating internal consis-
tency indexes (Cronbach’s alpha) for the five items on the OASIS.
To analyze the factor structure of the OASIS, we performed Confirmatory Factor Analysis
(CFA), a procedure based on Classical Test Theory (CTT) [45]. CFA models were estimated
with maximum likelihood and robust corrections (MLR), given the scale’s non-normality and
five-point response scale. Full Information Maximum Likelihood was employed to handle
missing data. Following Norman et al. [27], a single latent factor with correlated error vari-
ances between items 1 and 2 was tested as the basis for the CFA model. Model fit was evaluated
using several criteria, specifically, the chi-square test (χ2), comparative fitness index (CFI),
Tucker-Lewis index (TLI), standardized root mean residuals (SRMR), and root mean square
error of approximation (RMSEA). The following cutoff scores were used to determine good
fit: CFI and TLI above .90 (better if above .95) and RMSEA below .08 [46]. Following recom-
mendations by McNeish, An, & Hancock [47], factor loadings with their corresponding p val-
ues and the correlations between the error variances of the items were reported to evaluate the
validity of the factor model. A correlation between the error variance of items 1 and 2 was
expected because a response of 0 to item 1 (frequency of anxiety) would entail a response of 0
to item 2 (intensity of anxiety) [25].
Construct validity was examined through correlations with measures of anxiety (BAI),
depression (BDI-II), positive and negative affect (PANAS-P and PANAS-N), and quality of life
(QLI). Cohen’s [48] benchmarks for the interpretation of the correlation values were used,
where effect sizes between .10 and .30 are considered small, those between .30 and .50 are con-
sidered medium, and those of .50 or above are considered large.
To assess the sensitivity and specificity of the OASIS scores in detecting anxiety symptoms,
cutoff scores of the BAI scores were used to classify participants between those without anxiety
(BAI score< 10) and with anxiety (BAI score�10) [49]. The cutoff point on the BAI to assess
the sensitivity and specificity of the OASIS scores was 10, so that BAI scores�10 were consid-
ered to reflect anxiety symptoms. To examine the precision of the OASIS scores in detecting
cases with and without anxiety symptoms, the receiver operating characteristic (ROC) curve
was calculated, as well as the area under the curve (AUC). The AUC is a quantitative index
that combines sensitivity and specificity in order to provide information about the precision of
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a test score as a proportion, so that the larger the proportion, the greater the precision of the
test. The sensitivity of test scores is the proportion of positive cases (i.e., participants with anxi-
ety, assessed with the BAI) that are correctly identified by the OASIS scores. The specificity of
test scores is the proportion of negative cases (i.e., participants without anxiety, assessed by the
BAI) correctly identified by the OASIS scores as the best result. AUC values under .5 will
reflect lack of precision, whereas AUC values above .9 indicate excellent precision, values
between .7 and .9 indicate moderate precision, and values between .5 and .7 indicate mild pre-
cision. The AUC represents the probability that a participant randomly selected from the
group with anxiety will obtain a higher score on the OASIS than another participant, also ran-
domly selected, from the group of people without anxiety. A 95% confidence interval around
the AUC and its statistical significance were also calculated [50]. Sensitivity and specificity
were calculated for each cutoff point, as well as Positive Predictive Values (PPV), Negative Pre-
dictive Values (NPV), and their corresponding 95% confidence intervals. PPV represents the
proportion of cases correctly identified by the OASIS as positive with regard to all the positive
cases, whereas NPV represents the proportion of cases correctly identified as negative by the
OASIS with regard to all the negative cases. In order to identify the optimum cutoff point for
the OASIS, four methods were applied to each cutoff score [51]: the Youden index (J), Index of
Union (IU), Closest to (0, 1) Criteria (ER), and Concordance Probability Method (CZ). The
Youden index is defined as J = max(Sensitivity + Specificity -1), so that the OASIS cutoff point
that correspond to the maximum J value is considered the optimal cutoff point. The Index of
Union (IU) was calculated as IU = min(|Sensitivity–AUC| + |Specificity—AUC|). The IU is cal-
culated to guarantee that the sensitivity and specificity obtained at this cutoff point is simulta-
neously close to the AUC value, and the difference between the sensitivity and specificity
obtained at this cutoff point should be minimal. The Closest to (0, 1) Criteria is calculated as
ER ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
ð1   Sensitivity2 þ ð1   SpecificityÞ2
q
, and the optimal cutoff point according to this
index is defined as the point closest to the point (0, 1) on the ROC curve. Finally, the Concor-
dance Probability Method defines the optimal cutoff point as the point that maximizes the
product of sensitivity and specificity. CZ is calculated as CZ = Sensitivity�Specificity. The
OASIS score that met the four criteria, or most of them, was selected as the optimal cutoff
point.
Finally, in order to analyze sensitivity of OASIS scores to change, means and standard devi-
ations for the pretest and posttest were calculated with the OASIS scores from two studies
about the efficacy of Internet CBT in patients with emotional disorders. Part of the total sam-
ple completed the OASIS before and immediately after receiving an Internet-based treatment.
Thus, 24 patients received Smiling is Fun [52] (hereinafter subsample 1), and 68 patients
received Emotion Regulation [53,54] (hereinafter subsample 2). Smiling is Fun is an 8-module
Internet-based treatment for depression that includes components of evidence-based treat-
ments. The protocol stresses the importance and benefits of being active and staying involved
in life, values, and goals. It allows the individual to learn and practice adaptive ways to cope
with depressive symptoms and confront daily problems. Specifically, some components of Bar-
low’s Unified Protocol (UP) have been adapted, namely, motivation, psychoeducation, cogni-
tive therapy, and relapse prevention [55]. Furthermore, the program incorporates a Behavioral
Activation component [56] and a Positive Psychology component, which includes strategies to
promote and enhance personal strengths, positive feelings, positive cognitions, and positive
behavior [57,58]. Emotion Regulation is a 12-module transdiagnostic Internet-based treatment
for anxiety and depressive disorders. The treatment protocol is delivered through a multime-
dia web platform (https://www.psicologiaytecnologia.com/) (with videos, images, printable
documents, etc.), which allows participants easy and optimal use on a PC or tablet. The
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content of the protocol is adapted from the Unified Protocol [59] and from Marsha Linehan’s
protocol [60], with four core components: present-focused emotional awareness, cognitive
flexibility, behavioral and emotional avoidance patterns, and interoceptive and situational
exposure. The protocol also includes traditional therapeutic components of evidence-based
treatments, such as psychoeducation, motivation for change, and relapse prevention.
Minimum and maximum OASIS scores were also obtained from the pretest to check poten-
tial floor or ceiling effects. Evidence of floor or ceiling effects is present when more than 17%
of the participants obtained the lowest or highest possible score on the test, respectively (in our
case, 0 and 20). In addition, t-tests were applied to test the statistical significance of the pretest-
posttest mean differences. To quantify the OASIS scores’ sensitivity to change, the standard-
ized mean change index was used as the effect size, defined as the difference between the pre-
test and the posttest means divided by the standard deviation of the change scores. The
positive bias of the d index for small sample sizes was corrected with the c(m) correction factor
[61]:
d ¼ cðmÞ�yPre   �yPost=SDChange
with �yPre and �yPost being the pretest and posttest means, and c(m) being:
cðmÞ ¼ 1   3=4N   5
In addition, 95% confidence intervals for the d indices were calculated by means of
d ± 1.96xSE(d), with 1.96 being the 97.5 percentile of the standard normal distribution, and SE
(d) being the standard error of the d index [61]:
SEðdÞ ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
cðmÞ2xð1=nÞxðn   1=n   3Þxð1þ nd2Þ   d2
q
All of these calculations were applied separately for subsamples 1 and 2. To offer a contextu-
alized interpretation of the d indices obtained in subsamples 1 and 2, we used the results of a
systematic review of meta-analyses carried out on the efficacy of psychological treatments that
applied the standardized mean change index as the effect size [62]. In this review, percentiles
25, 50, and 75 of the d indices’ distribution were 0.64, 0.75, and 1.26. Therefore, a reasonable
interpretation of these three values is to consider them as reflecting low, moderate, and large
magnitudes of the effect.
CFA was calculated using the EQS program, version 6.1. Sensitivity, specificity, PPV, and
NPV were calculated using a web application (http://vassarstats.net/clin1.html). The software
SPSS Statistics version 22.0 was used for the remaining analyses.
Results
Preliminary analyses
The mean OASIS score was 8.69 (SD = 4.21) in the total sample (n = 583), 8.92 (SD = 4.28) for
females (n = 421), and 8.15 (SD = 3.96) for the male participants (n = 162). Tables 2 and 3
show descriptive statistics for each item and the total score on the OASIS, and for the remain-
ing instruments, for both the depressive and anxiety disorder samples, respectively.
Significant differences were found in the OASIS scores based on the number of comorbid
disorders (F = 6.91; p< .001), with higher anxiety levels found the participants with a larger
number of comorbid disorders. There were no significant differences based on sex, civil status,
education level, or principal diagnosis. In addition, no statistical relationships were observed
between the participants’ age and OASIS scores.
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Factor structure
A single-factor model resulted in an adequate model fit: χ24 = 11.693, p> .01; SRMR = .027;
RMSEA = .058, 90% CI [.015, .104]; CFI = .995. Factor loadings showed that all the items were
strongly related to this factor, with values ranging from .65 to .82 All these values reached sig-
nificance at p< .05 (see Fig 1).
Internal consistency
Cronbach’s alpha for the five items on the OASIS was .86. Table 4 shows the results for Cron-
bach’s alpha when omitting items, corrected correlations between each item and the total
score, and correlations between the five items of the OASIS. The results obtained indicate
good internal consistency of the OASIS that would not be increased by excluding any item.
Convergent validity
Table 5 shows the correlation between the OASIS and the convergent validity measures. A
large positive correlation was expected between the OASIS and the BAI. A positive but
medium correlation was expected between the OASIS and the BDI-II. Given the theoretical
and empirical associations between the dimensions of positive and negative affect and anxiety
[2], we anticipated a positive but medium correlation between the OASIS and the PANAS-N,
and a negative and medium correlation with the PANAS-P. Finally, we anticipated a negative
and medium correlation between the OASIS and QLI (quality of life). All these results were
interpreted as evidence for convergent validity.
Table 2. Descriptive statistics for each item and the total score on the OASIS in depressive and anxiety disorder samples.
Anxiety sample (n = 250) Depression sample (n = 333)
M SD λ1 λ2 M SD λ1 λ2
Item 1 1.96 1.06 .108 -.466 2.05 1.04 -.145 -.881
Item 2 1.80 .88 -.157 -.911 1.79 .86 -.285 -.124
Item 3 1.56 1.16 .330 -.049 1.65 1.13 .246 -.684
Item 4 1.61 1.08 .229 -.723 1.70 1.05 -.087 -.925
Item 5 1.53 1.11 .371 -.808 1.70 1.06 -.045 -.697
Total score 8.37 4.29 .230 -.624 8.96 4.17 -.190 -.420
M = Mean; SD = Standard deviation; λ1 = skewness; λ2 = kurtosis
https://doi.org/10.1371/journal.pone.0206516.t002
Table 3. Descriptive statistics for convergent and discriminant validity measures in depressive and anxiety disorder samples.
Anxiety sample Depression sample
M SD λ1 λ2 M SD λ1 λ2
BAI 20.41 11.94 .451 -.588 19.13 11.39 -.690 -.008
BDI-II 21.74 11.45 .284 -.339 24.70 10.70 .409 .331
ODSIS 6.41 4.93 .384 -.899 8.64 4.68 -.107 -.778
PANAS-P 23.45 8.13 .695 .073 19.64 6.53 .828 .317
PANAS-N 27.24 7.81 .110 -.574 25.32 7.98 .286 -.282
QLI 4.94 1.66 .041 -.473 4.51 1.71 .275 -.407
M = Mean; SD = Standard deviation; λ1 = skewness; λ2 = kurtosis; BAI = Beck Anxiety Inventory; BDI-II = Beck Depression Inventory-II; ODSIS = Overall Depression
Severity and Impairment Scale; PANAS-P = Positive and Negative Affect Schedule-Positive Affect; PANAS-N = Positive and Negative Affect Schedule-Negative Affect;
QLI = Multidimensional Quality of Life Questionnaire
https://doi.org/10.1371/journal.pone.0206516.t003
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The OASIS correlated significantly with all the measures. As predicted, positive and large
correlations were found between the OASIS and the BAI (r = .61, p< .01). In addition, large
and positive correlations were found between the OASIS and the BDI-II (r = .60, p< .01), and
between the OASIS and the ODSIS (r = .65, p< .01). The OASIS correlated largely with the
PANAS-N (r = .60, p< .01). Finally, the analyses yielded a negative medium correlation
between the OASIS and the PANAS-P (r = -.40, p< .01), and a negative large correlation
between the OASIS and the QLI (r = -.58, p< .01).
Receiver operating characteristic (ROC)
A ROC curve was calculated in the sample when a cutoff point� 10 was applied to the BAI
scores. The AUC obtained was .817 (95%CI: .731 and .903) and reached statistical significance
Fig 1. Confirmatory factor analysis (CFA) model. Rectangles are measured variables, the large circle is the latent construct, and
small circles are residual variances. Factor loadings are standardized. All values are significant at p< .05. The solution specified
correlated error variance between items 1 and 2.
https://doi.org/10.1371/journal.pone.0206516.g001
Table 4. Cronbach’s alpha if item is deleted, corrected item-total score correlation, and correlations between items.
Cronbach’s Alpha if item deleted Corrected item-total correlation Correlations between items
Item 1 Item 2 Item 3 Item 4 Item 5
Item 1 .842 .658 1
Item 2 .838 .692 .689� 1
Item 3 .849 .640 .422� .464� 1
Item 4 .825 .726 .560� .585� .587� 1
Item 5 .824 .729 .543� .543� .643� .628� 1
�Correlation was significant at p< .01 (two-tailed)
https://doi.org/10.1371/journal.pone.0206516.t004
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(p< .001). This AUC can be interpreted as indicating that there was a .817 probability of ran-
domly selecting a participant from the anxiety group (i.e., with a BAI score� 10) with an
OASIS score higher than that of any other participant, also randomly selected, from the group
without anxiety (i.e., with BAI score< 10). An AUC = .817 can also be interpreted as reflecting
moderate precision from a clinical point of view. Therefore, the precision of the OASIS scores
in detecting any type of anxiety (mild, moderate, or severe) can be considered to have a moder-
ate magnitude. Table 6 presents the sensitivity, specificity, PPV, and NPV obtained with the
OASIS scores for the cutoff point� 10 on the BAI. The table also shows the results of the four
methods used to select the optimal cutoff score for the OASIS (Youden index, J, Index of
Union, IU, the Closest to (0, 1) Criteria, ER, and the Concordance Probability Method, CZ).
The OASIS score = 7.5 met three of the four criteria (IU, ER, and CZ criteria); regarding the
Youden index, this score obtained the second best value (.498), very close to the maximum
value obtained with this method (.503). Therefore, 7.5 was selected as the optimal cutoff point
to detect anxiety symptoms (i.e., OASIS scores over 7 indicate anxiety symptoms). For this cut-
off point, sensitivity was .727 (95%CI: .650; .792), and specificity was .771 (95% CI: .594; .889).
PPV was .936 (95% CI: .874; .970), and NPV was .380 (95% CI: .270; .504).
Analysis of sensitivity to change
Two subsamples were used for the analysis of sensitivity to change. Subsample 1 consisted of
24 patients who completed an Internet-based treatment for depression [52], and subsample 2
was made up of 68 patients who underwent a transdiagnostic Internet-based treatment for
anxiety and depressive disorders [53,54]. To examine potential floor and ceiling effects for the
OASIS scores, the frequency and percentage of minimum (0) and maximum (20) scores was
tabulated for subsamples 1 and 2 on the pretest. The results showed that only 2 patients out of
24 (12%) in subsample 1, and 3 out of 68 in subsample 2 obtained a score of 0 (minimum). In
addition, no patient in any of the subsamples obtained a score of 20 (maximum). Therefore,
evidence of floor and ceiling effects can be ruled out, as the percentage was lower than 17% in
all cases.
To examine the sensitivity to change of the OASIS scores, means and standard deviations
were calculated for each subsample, both on the pretest and the posttest. The statistical signifi-
cance of the pretest-posttest change scores was assessed by applying t-tests, which, as Table 7
reveals, were statistically significant for both studies. The clinical significance was assessed by
means of the effect size index ‘standardized mean change index’ (d). Following Rubio-Aparicio
Table 5. Correlations of the OASIS with convergent validity measures.
OASIS BAI ODSIS BDI-II PANAS-P PANAS-N QLI
OASIS - .61� .65� .60� -.40� .60� -.58�
BAI - .35� .47� -.25� .53� -.41�
ODSIS - .67� -.57� .49� -.69�
BDI-II - -.56� .57� -.76�
PANAS-P - -.32� .71�
PANAS-N - -.48�
QLI -
�Correlation was statistically significant at p< .01 (two-tailed)
OASIS = Overall Anxiety Severity and Impairment Scale, BAI = Beck Anxiety Inventory, ODSIS = Overall Depression Severity and Impairment Scale, BDI-II = Beck
Depression Inventory-II, PANAS-P = Positive and Negative Affect Schedule-Positive Affect, PANAS-N = Positive and Negative Affect Schedule-Negative Affect,
QLI = Multidimensional Quality of Life Questionnaire
https://doi.org/10.1371/journal.pone.0206516.t005
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et al. results [62], subsamples 1 and 2 obtained d indices that can be interpreted as reflecting
moderate (d = 0.72) and moderate-to-large (d = 0.90) clinical relevance, respectively.
Discussion
The aim of this study was to analyze the psychometric properties of the online version of the
OASIS in a Spanish sample of patients with emotional disorders. This study evaluated the reli-
ability, construct validity, and latent structure of the OASIS. In addition, cutoff scores were
obtained, and sensitivity to change was examined.
First, preliminary analyses showed that patients with more comorbid disorders were signifi-
cantly more anxious than patients with fewer comorbid disorders, a finding that was some-
what expected given the strong association observed between comorbidity and severity [63].
By contrast, no statistically significant differences were found based on sex, education level,
marital status, or principal diagnosis (i.e. anxiety disorder vs. depressive disorder), which,
Table 6. Statistics to assess the diagnostic accuracy of the OASIS scores.
OASIS score Se Sp PPV NPV J IU ER CZ
0.5 .994 .171 .846 .857 .165 .823 .829 .170
1.5 .994 .200 .851 .875 .194 .794 .800 .199
2.5 .975 .314 .867 .733 .289 .661 .686 .306
3.5 .969 .457 .891 .762 .426 .512 .544 .443
4.5 .932 .571 .909 .645 .503 .361 .434 .532
5.5 .876 .600 .910 .512 .476 .276 .419 .526
6.5 .814 .657 .916 .434 .471 .163 .390 .535
7.5 .727 .771 .936 .380 .498 .136 .356 .561
8.5 .627 .800 .935 .318 .427 .207 .423 .502
9.5 .528 .857 .944 .283 .385 .329 .493 .452
10.5 .435 .914 .959 .260 .349 .479 .572 .398
11.5 .354 .914 .950 .235 .268 .560 .652 .324
12.5 .242 .914 .928 .208 .156 .672 .763 .221
13.5 .161 .971 .963 .201 .132 .810 .840 .156
14.5 .124 1 1 .199 .124 .876 .876 .124
15.5 .093 1 1 .193 .093 .907 .907 .093
16.5 .043 1 1 .185 .043 .957 .957 .043
17.5 .019 1 1 .181 .019 .981 .981 .019
18.5 .006 1 1 .179 .006 .994 .994 .006
20 0 1 NA NA 0 1 1 0
Se = Sensitivity; Sp = Specificity; PPV = Positive Predictive Value; NPV = Negative Predictive Value; J = Youden index; IU = Index of Union; ER = Closest to (0, 1)
Criteria; CZ = Concordance Probability Method; NA = Not applicable.
https://doi.org/10.1371/journal.pone.0206516.t006
Table 7. Descriptive and inferential results from the two subsamples for the OASIS scores on the pretest and the posttest.
Subsample N Pretest Posttest t d
Mean SD Mean SD
1 24 6.42 3.46 3.00 2.62 3.65��� 0.72 [0.26, 1.18]
2 68 8.59 4.41 4.50 4.60 7.44��� 0.90 [0.61, 1.19]
���p< .001
N = sample size; SD = standard deviation; t = t statistic for testing the pretest-posttest mean difference; d = standardized mean change index (95% CI in brackets).
https://doi.org/10.1371/journal.pone.0206516.t007
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taken together, suggests that the Spanish version of the OASIS can be used indistinctly across
patients with different sociodemographic and clinical characteristics. In this vein, it is impor-
tant to note that a large proportion of patients in this study (53.5%) presented at least with one
anxiety or depressive disorder. Second, regarding reliability, the five items on the OASIS dem-
onstrated good internal consistency (alpha = .86). Third, as in previous validations of the
instrument [25–27], confirmatory factor analysis revealed a unidimensional factor structure.
Moreover, as expected, the model showed correlated error variance between items 1 and 2.
Regarding the ROC analysis, a cutoff point of 7.5 was found to meet three of the four crite-
ria used to select the optimal cutoff point (i.e. Index of Union, Closest to (0, 1) Criteria, and
Concordance Probability Method). These findings suggest that this score (i.e. scores above 7 at
the OASIS) can be used as a cutoff point to discriminate between patients with anxiety symp-
toms of clinical consideration vs. anxiety symptoms of no clinical consideration. This informa-
tion might be useful, for instance, for screening and selecting patients with anxiety symptoms
for clinical trials. The results obtained in this study using ROC curves are consistent with prior
validations of the instrument in clinical populations, which showed that cutoff scores of
around 8 differentiate anxious patients from non-anxious patients [25,27].
This study also examined sensitivity to change by analyzing the significance of the improve-
ments from pre- to post-treatment on the OASIS scores. The analyses showed moderate to
large effect sizes (Cohen’s d between .72 and .90), which suggests that the scale can not only be
used for screening purposes (i.e. by using the cut-off point), but also that it is able to detect
changes in anxiety and therefore it can be used to examine the impact of an intervention.
Regarding construct validity, positive and large correlations were found between the OASIS
and the BAI, as anticipated, which is interpreted in this study as evidence of adequate conver-
gent validity with one of the most widely used questionnaires for the assessment of anxiety.
The fact that the OASIS also correlated significantly with measures of positive and negative
affectivity, but less than with measures of anxiety (i.e. BAI), was interpreted as evidence for the
discriminant validity of the instrument. Finally, although we predicted medium correlations
between the OASIS and the depression measures (i.e. ODSIS and BDI-II), the results showed
large correlations between these measures. In this regard, it is important to note that a large
proportion of the patients (53.5%) had comorbid depressive or anxiety disorders, which might
account for the large correlations between anxiety and depression obtained in this study. Over-
all, the results obtained in this study were interpreted as evidence for construct validity.
Overall, the results of this study are consistent with those obtained in prior validations of
the scale [25,31,32], and they support the adequacy of the OASIS as a valid measure for the
online assessment of the anxiety severity and impairment associated with anxiety symptoms.
This study has several strengths. First, to the best of our knowledge, this is the first
study to evaluate the psychometric properties of the OASIS in a Spanish clinical sample of
individuals with anxiety and depressive disorders. Brief instruments to assess the severity
and impairment related to anxiety are lacking in Spain, and so this study contributes to
filling the gap in this particular field. Second, although the OASIS has already been vali-
dated in transdiagnostic samples with emotional disorders [31], the sample size of patients
with principal diagnoses of a depressive disorder was larger in this study. Unlike the study
by Bragdon et al. [31], in which most patients had a principal diagnosis of an anxiety dis-
order (85.6%), we used a sample with a more balanced number of patients with a principal
diagnosis of anxiety (55.2%) versus depression (44.8%). Given the burden and prevalence
of depression, as well as its transdiagnostic nature and high comorbidity rates with anxiety
disorders [2], the findings obtained in this study contribute to the literature on the OASIS
by providing data about how the scale performs in patients with a principal diagnosis of
depression. Third, the large sample size used in this study (n = 583), and its high
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diagnostic heterogeneity (i.e. individuals with a variety of anxiety and depressive disor-
ders), helps to increase the generalizability of the results obtained in the study. Fourth,
although various validations of the OASIS have been performed in clinical samples
[25,31,33,64], none of them have analyzed how the scale performs as a treatment outcome
measure. Following previous recommendations [31,64], in this study we intended to con-
tribute to filling this gap by analyzing sensitivity to change in two subsamples of patients
who received Internet treatments. Fifth, all the patients in the study completed the OASIS
through online surveys. Therefore, the results obtained in this study suggest that the
online version of the OASIS is an adequate instrument for the online assessment of anxi-
ety (e.g. in trials examining Internet treatments, where both the assessment and the treat-
ment are delivered through an online platform). Given the proliferation of Internet-based
treatments in the past decade, the need for validated online assessment instruments is
greater than ever before.
Limitations
This study has some limitations that should be acknowledged. First, test-retest reliability was
not evaluated in this study. Because all the participants in this study were derived from clinical
samples that were receiving treatment, we were not able to analyze this aspect. Second, we
were not able to analyze sensitivity to change with the entire sample because scores from pre-
to post-treatment were not available for all participants in this study. Moreover, we were not
able to examine the sensitivity to change of the OASIS compared to other scales for the assess-
ment of anxiety, such as the BAI. Third, it might have been useful to include additional mea-
sures of anxiety in this study to further evaluate the convergent validity of the OASIS.
However, it is important to note that the inclusion of instruments in this study was determined
by the fact that all the patients were derived from trials where the selection of instruments was
already pre-specified. For this reason, only two measures for the assessment of anxiety were
used in this study (OASIS and BAI). Fourth, even though the BAI is a well-established measure
and one of the more widely used scales for the assessment of anxiety [65–67], we did not follow
the optimum approach for the calculation of the ROC curve because the classification of sub-
jects was based on a cutoff from a scale (BAI) rather than a group of healthy control individu-
als. Hence, the cutoff score obtained in this study should be considered with caution. Finally,
the proportion of females and males in this study was not balanced, which might affect the
representativity of the results. However, the proportion of females versus males in this study is
likely to have been affected by the higher prevalence rates of anxiety and depressive disorders
in females compared to males [68].
Conclusions
In conclusion, the results obtained in this study support the adequacy of the online version of
the OASIS in clinical samples of Spanish patients with anxiety and depressive disorders. The
brevity and ease of use of the OASIS makes this scale an adequate tool for the quick screening
of the severity and impairment associated with anxiety. Future validations of the OASIS should
analyze its sensitivity to change in comparison with other measures of anxiety, in order to
draw firmer conclusions about this aspect.
The psychometric properties of the online version of the OASIS were analyzed in this
study. Similarly to evidence-based online treatments, the validation of online scales can have a
direct impact in the dissemination of evidence-based methods for the assessment of behav-
ioral, cognitive and psychopathological processes.
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